Close

Anti-Peptide GPQ T cell receptor (T15), pCDTCR1 (TCR-YC0915)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Unlike the Bel602 TCR, the T15 TCR possessed an Arg within its CDR3b loop, and it was of interest to compare how the T15 TCR and Bel602 TCR bound the DQ8.5-glia-g1 determinant. The T15 TCR engaged HLA-DQ8.5-glia-g1 in a similar docking position to the Bel602 TCR_x0004_. The salient features at the T15 TCR-HLA-DQ8.5-glia-g1 and Bel602 TCR-HLA-DQ8.5- glia-g1 interfaces were similar, including the role of the germline-encoded Arg37a from the TCR a chain as well as Leu37b and Tyr57b from the TCR b chain.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • Peptide GPQ
  • Epitope
  • GPQQSFPEQEA
  • Format
  • Non-Modified TCR
  • Allele
  • HLA-DQA1*05:01/DQB1*03:02
  • Targeting Diseases
  • HLA-DQ8–associated celiac disease (CD)
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • T15
  • Host Species
  • Human

Target

  • Introduction
  • In HLA-DQ8-associated celiac disease, TRAV26-2+ - TRBV9+ and TRAV8-3+ -TRBV6+ T cells recognize the immunodominant DQ8-glia-a1 epitope, whereupon a non-germline-encoded arginine residue played a key role in binding HLA-DQ8-glia-a1.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-Peptide GPQ T cell receptor (T15), pCDTCR1 (TCR-YC0915). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.